HealthVerity
Summary New Core Watchlist Market Weak signals Manual checks Gaps & log Sources
Executive summary
- HealthVerity closed its Symphony Health acquisition on May 8, 2026 as an all-stock merger — it paid in its own shares while seller ICON separately invested $37.5M cash for a minority HealthVerity stake that ICON immediately carries at $nil. ↳
- The deal is a capital-efficient up-stack carve-out: HealthVerity preserved cash by issuing equity, and bought a 40-year commercial-data asset from a financially stressed ICON (bridge credit facility + debt waivers, late April 2026). ↳
- The combined company's explicit strategy — stated in the live SVP, Product req — is to move from data sales into higher-margin AI software-and-services, including LLM abstraction of clinical notes and agentic workflows embedded in client systems. ↳
- Symphony moves HealthVerity up-stack from neutral identity/linkage into pharma commercial analytics — newly overlapping Inovalon's Insights/RWD life-sciences business even as HealthVerity remains Inovalon's preferred linkage supplier (a frenemy dynamic). ↳
- The merged portfolio is positioned as one 'AI-ready' life-sciences platform spanning HealthVerity Marketplace/Identity Manager/eXOs/Audiences and Symphony's IDV open claims, Synoma tokenization and PatientSource. ↳
- Thermo Fisher's PPD took enterprise access to HealthVerity's Taxonomy claims dataset (270M+ lives) in April 2026 — notable because PPD also sources RWD from Datavant, signaling multi-vendor demand-side behavior. ↳
- Hiring skews to a leadership/integration build-out (SVP Product, VP PMO, VP Tech Ops, Sr Dir BD-Partners, dual VP Strategic Accounts, pre/post-sale Lead Data Analysts) — integration scaffolding plus a services/insights motion, not IC engineering scale. ↳
New since last run
factnew Per ICON's 20-F, HealthVerity acquired Symphony Health on May 8, 2026 via an all-stock merger (consideration was HealthVerity shares), ICON separately purchased $37.5M of additional HealthVerity stock to take a minority equity interest, and ICON records that HealthVerity investment at a carrying value of $nil.
inferencenew HealthVerity's Symphony acquisition is a capital-efficient up-stack carve-out — funded with its own equity rather than cash, acquired from a financially stressed ICON that entered a bridge secured credit facility and debt-agreement waivers in late April 2026 and took paper (a $nil-carried minority stake) instead of cash.
factnew HealthVerity positions the merged entity as a single 'AI-ready' life-sciences data platform uniting its own assets (Marketplace, Identity Manager, eXOs 'AI-native RWE', Notes, Mastersets, Taxonomy/Pathways, Audiences, Media Measurement, Clinical Trial Linkage) with Symphony's commercial stack (Integrated Dataverse open claims, Synoma tokenization, PatientSource longitudinal data, brand/targeting/managed-markets analytics).
factnew HealthVerity's live SVP, Product req (reporting to the CEO with an executive-team seat) sets the combined-company mandate to move 'from data sales into higher-margin, differentiated software-and-services offerings,' owning an AI product strategy spanning LLM abstraction of unstructured clinical data, retrieval/summarization across longitudinal records, predictive patient-finding/brand models, and agentic workflows operationalized inside client systems.
inferencenew Acquiring Symphony moves HealthVerity up-stack from neutral identity/linkage infrastructure into pharma commercial analytics (brand, targeting, managed markets, sell-in), newly overlapping Inovalon's Insights/RWD life-sciences business while HealthVerity simultaneously remains Inovalon's preferred external linkage supplier — a supplier-turned-partial-competitor dynamic.
inferencenew HealthVerity's 14-role board skews to a leadership/integration build-out — SVP Product, VP PMO, VP Technology Operations, VP Marketing, Senior Director BD (Partners), two VP Strategic Accounts (incl. West), and pre/post-sale Lead Healthcare Data Analysts — signaling post-merger integration scaffolding plus a services/insights motion rather than IC engineering scale-up.
factnew In April 2026 Thermo Fisher's PPD clinical-research business took enterprise-level access to HealthVerity's Taxonomy claims dataset (270M+ de-identified US patient lives) for trial feasibility, recruitment, and RWE generation — and PPD separately sources RWD from Datavant, evidencing multi-vendor demand-side behavior among large CROs.
factnew Symphony Health's Integrated Dataverse (now a HealthVerity asset) is named as the data source in a 2026 Journal of Managed Care & Specialty Pharmacy study (ViiV's long-acting cabotegravir/rilpivirine ABOVE study), one of a cluster of 2026 claims-database pharmacoepi papers surfacing under HealthVerity/Symphony asset-term search.
inferencenew AI sits at the leadership/product layer rather than broad IC hiring — 'agentic,' 'generative,' and 'LLM' language concentrates in the SVP Product and Healthcare-Media Solutions-Engineer reqs, and the only branded AI product (eXOs 'AI-native real-world evidence generation') is HealthVerity's, with Symphony contributing data assets rather than AI tooling.
factnew HealthVerity holds an established federal/government data footprint that predates this window — HHS contracts for COVID-19 immunization privacy-preserving record linkage ($1.99M, 2022) and 'HEROES' data variables ($1.01M, 2024) — substantiating the 'government' client segment the SVP Product role is chartered to grow.
Core competitors
Watchlist headlines
HealthVerity
factnew Per ICON's 20-F, HealthVerity acquired Symphony Health on May 8, 2026 via an all-stock merger (consideration was HealthVerity shares), ICON separately purchased $37.5M of additional HealthVerity stock to take a minority equity interest, and ICON records that HealthVerity investment at a carrying value of $nil.
inferencenew HealthVerity's Symphony acquisition is a capital-efficient up-stack carve-out — funded with its own equity rather than cash, acquired from a financially stressed ICON that entered a bridge secured credit facility and debt-agreement waivers in late April 2026 and took paper (a $nil-carried minority stake) instead of cash.
factnew HealthVerity positions the merged entity as a single 'AI-ready' life-sciences data platform uniting its own assets (Marketplace, Identity Manager, eXOs 'AI-native RWE', Notes, Mastersets, Taxonomy/Pathways, Audiences, Media Measurement, Clinical Trial Linkage) with Symphony's commercial stack (Integrated Dataverse open claims, Synoma tokenization, PatientSource longitudinal data, brand/targeting/managed-markets analytics).
factnew HealthVerity's live SVP, Product req (reporting to the CEO with an executive-team seat) sets the combined-company mandate to move 'from data sales into higher-margin, differentiated software-and-services offerings,' owning an AI product strategy spanning LLM abstraction of unstructured clinical data, retrieval/summarization across longitudinal records, predictive patient-finding/brand models, and agentic workflows operationalized inside client systems.
inferencenew Acquiring Symphony moves HealthVerity up-stack from neutral identity/linkage infrastructure into pharma commercial analytics (brand, targeting, managed markets, sell-in), newly overlapping Inovalon's Insights/RWD life-sciences business while HealthVerity simultaneously remains Inovalon's preferred external linkage supplier — a supplier-turned-partial-competitor dynamic.
inferencenew HealthVerity's 14-role board skews to a leadership/integration build-out — SVP Product, VP PMO, VP Technology Operations, VP Marketing, Senior Director BD (Partners), two VP Strategic Accounts (incl. West), and pre/post-sale Lead Healthcare Data Analysts — signaling post-merger integration scaffolding plus a services/insights motion rather than IC engineering scale-up.
factnew In April 2026 Thermo Fisher's PPD clinical-research business took enterprise-level access to HealthVerity's Taxonomy claims dataset (270M+ de-identified US patient lives) for trial feasibility, recruitment, and RWE generation — and PPD separately sources RWD from Datavant, evidencing multi-vendor demand-side behavior among large CROs.
factnew Symphony Health's Integrated Dataverse (now a HealthVerity asset) is named as the data source in a 2026 Journal of Managed Care & Specialty Pharmacy study (ViiV's long-acting cabotegravir/rilpivirine ABOVE study), one of a cluster of 2026 claims-database pharmacoepi papers surfacing under HealthVerity/Symphony asset-term search.
inferencenew AI sits at the leadership/product layer rather than broad IC hiring — 'agentic,' 'generative,' and 'LLM' language concentrates in the SVP Product and Healthcare-Media Solutions-Engineer reqs, and the only branded AI product (eXOs 'AI-native real-world evidence generation') is HealthVerity's, with Symphony contributing data assets rather than AI tooling.
Market & demand signals
factnew HealthVerity holds an established federal/government data footprint that predates this window — HHS contracts for COVID-19 immunization privacy-preserving record linkage ($1.99M, 2022) and 'HEROES' data variables ($1.01M, 2024) — substantiating the 'government' client segment the SVP Product role is chartered to grow.
Weak signals
Single-signal inferences — interpret with caution.
inferenceweak signalnew ICON's retained minority stake plus its $37.5M cash co-investment leave the CRO financially tied to HealthVerity's combined-entity success — plausibly preserving Symphony-data continuity for ICON's own trials, though the $nil carrying value signals ICON assigns the stake no balance-sheet value.
Manual checks
Search Andrew Kress (CEO) and HealthVerity company-page posts since 2026-05-08 for combined-org leadership announcements and who fills the SVP, Product role; the hire's background (IQVIA/Symphony/payer vs pharma-commercial) signals the portfolio's center of gravity. — https://www.linkedin.com/company/healthverity/posts/
Search 'Symphony Health' current employees and recent title changes to gauge whether Symphony's brand-analytics/managed-markets leaders are being retained or attriting post-close — a key integration-risk read. — https://www.linkedin.com/search/results/people/?keywords=Symphony%20Health
EDGAR full-text search surfaced HealthVerity in Recursion Pharmaceuticals' 10-K/ARS and Veeva's DEF 14A; read the context to confirm whether HealthVerity is named as a data supplier, partner, or competitive-landscape reference. — https://efts.sec.gov/LATEST/search-index?q=%22HealthVerity%22
Owner-name search HealthVerity and Symphony Health in the USPTO tmsearch UI for new marks filed since May 2026 — a combined-platform or product-rebrand filing would signal how they package the merged portfolio. — https://tmsearch.uspto.gov/search/search-results?query=HealthVerity[OW]&type=web
Browse Snowflake and AWS Data Exchange marketplaces for new or updated HealthVerity/Symphony combined listings (e.g., IDV open claims via HealthVerity), which would be the first concrete sign of integrated productization. — https://app.snowflake.com/marketplace?search=HealthVerity
Coverage gaps & run log
Coverage gaps
| Company | Category | Reason |
|---|---|---|
| HealthVerity | regulatory | all 2 scripted attempt(s) empty/failed (cap 4 for core tier) |
| HealthVerity | trials | 11 ClinicalTrials.gov 'Symphony Health' term hits were all medical-device name collisions (Symphony IL-6 sepsis monitor, Symphony cervical system, Symphony thrombectomy); HealthVerity/IDV/PatientSource data assets appear in zero in-window trial registrations. Asset-as-data-source is under-registered on CT.gov, so absence is weak evidence, not proof of non-use. |
| HealthVerity | publications | PubMed asset-term search high-noise: 'PHAST'/'Synoma'/'PatientSource' collided with unrelated assays, polymers, and engineering papers. Only Symphony-IDV-as-data-source was manually confirmed (PMID 42043923); the broader claims-database cluster needs per-paper data-source confirmation before counting. |
Query log
| Source | Query | Results | Status |
|---|---|---|---|
| clinicaltrials | ct sponsor=HealthVerity | 0 | ok |
| clinicaltrials | ct term=Integrated Dataverse | 0 | ok |
| clinicaltrials | ct term=Symphony Health | 11 | ok |
| clinicaltrials | ct term=PatientSource | 0 | ok |
| openfda-510k | 510k applicant=HealthVerity | 0 | ok |
| openfda-pma | pma applicant=HealthVerity | 0 | ok |
| pubmed | pubmed HealthVerity | 35 | ok |
| nih_reporter | reporter text=HealthVerity | 0 | ok |
| edgar-fts | edgar fts HealthVerity | 7 | ok |
| jobs | jobs HealthVerity | 14 | ok |
| usaspending | usaspending HealthVerity | 2 | ok |
| pages | pages HealthVerity | 1 | ok |
| websearch | HealthVerity completes acquisition Symphony Health ICON plc 2026 | 6 | ok |
| websearch | HealthVerity Symphony Health combined company product AI launch 2026 | 10 | ok |
| websearch | HealthVerity partnership announcement 2026 pharma data | 8 | ok |
| websearch | HealthVerity CEO Andrew Kress revenue funding 2026 Symphony | 9 | ok |
| websearch | ICON plc Symphony Health divestiture sale price proceeds gain disposal | 10 | ok |
| webfetch | healthverity.com completes-acquisition PR (assets/quotes/AI) | 1 | ok |
| webfetch | contractpharma Thermo Fisher/PPD partnership | 0 | error: 403 WAF |
| webfetch | ICON 20-F via ci_http — Symphony/HealthVerity disposal terms | 1 | ok |
| webfetch | PubMed 42043923 ABOVE study data-source verification | 1 | ok |
Sources
HealthVerity
- https://www.sec.gov/Archives/edgar/data/1060955/000162828026038487/iclr-20251231.htm
- https://www.tikr.com/blog/is-icon-stock-finally-priced-for-recovery-after-a-3-9b-backlog-cut-and-a-q4-2025-eps-miss
- https://healthverity.com/news/healthverity-completes-acquisition-of-symphony-health-marking-a-new-era-for-the-healthcare-data-industry/
- https://www.globenewswire.com/news-release/2026/05/05/3287615/0/en/healthverity-to-acquire-symphony-health-uniting-clinical-data-and-commercial-analytics-to-accelerate-breakthroughs-across-the-healthcare-ecosystem.html
- https://healthverity.com/careers/jobs/?gh_jid=5233266008
- https://www.mobihealthnews.com/news/healthverity-acquire-data-platform-symphony-health
- https://boards-api.greenhouse.io/v1/boards/healthverity/jobs
- https://healthverity.com/careers/jobs/?gh_jid=5211504008
- https://www.appliedclinicaltrialsonline.com/view/thermo-fisher-ppd-real-world-data-access-healthverity-collaboration
- https://www.contractpharma.com/breaking-news/thermo-fisher-scientific-healthverity-partner-to-expand-real-world-data-capabilities/
- https://pubmed.ncbi.nlm.nih.gov/42043923/
- https://www.usaspending.gov/award/CONT_AWD_75D30122C13317_7523_-NONE-_-NONE-
- https://www.usaspending.gov/award/CONT_AWD_75N99224P00002_7529_-NONE-_-NONE-